Dendritic cell-based immunity and vaccination against hepatitis C virus infection
Article first published online: 2 JUL 2012
© The Authors. Immunology © Blackwell Publishing Ltd
Volume 136, Issue 4, pages 385–396, August 2012
How to Cite
Zhou, Y., Zhang, Y., Yao, Z., Moorman, J. P. and Jia, Z. (2012), Dendritic cell-based immunity and vaccination against hepatitis C virus infection. Immunology, 136: 385–396. doi: 10.1111/j.1365-2567.2012.03590.x
- Issue published online: 2 JUL 2012
- Article first published online: 2 JUL 2012
- Accepted manuscript online: 5 APR 2012 12:52PM EST
- Received 30 January 2012; revised 2 March 2012; accepted 20 March 2012.
- dendritic cells;
- hepatitis C virus;
- vaccine development
Hepatitis C virus (HCV) has chronically infected an estimated 170 million people worldwide. There are many impediments to the development of an effective vaccine for HCV infection. Dendritic cells (DC) remain the most important antigen-presenting cells for host immune responses, and are capable of either inducing productive immunity or maintaining the state of tolerance to self and non-self antigens. Researchers have recently explored the mechanisms by which DC function is regulated during HCV infection, leading to impaired antiviral T-cell responses and so to persistent viral infection. Recently, DC-based vaccines against HCV have been developed. This review summarizes the current understanding of DC function during HCV infection and explores the prospects of DC-based HCV vaccine. In particular, it describes the biology of DC, the phenotype of DC in HCV-infected patients, the effect of HCV on DC development and function, the studies on new DC-based vaccines against HCV infection, and strategies to improve the efficacy of DC-based vaccines.